Clinical trial
Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer
NCT00438100 · Japan Breast Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00438100 |
|---|---|
| Title | Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer |
| Official title | Randomized Control Study of Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer Patients |
| Lead sponsor | Japan Breast Cancer Research Network, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Capecitabine, S-1 |
| Enrollment | 142 |
| Start date | Apr 1, 2008 |
| Primary completion | Jul 1, 2012 |
| Completion | May 1, 2013 |
| First posted | Feb 21, 2007 |
| Last update posted | May 29, 2015 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: